# Retatrutide: Research Overview — Vyra Peptides > A literature summary of retatrutide (LY3437943), an investigational GIP/GLP-1/glucagon triple agonist in Phase 3 trials. Covers triple-receptor mechanism, Phase 2 weight-loss data (~24%), liver fat results, and safety profile. Phase 2 data showing ~24% body-weight reduction at 48 weeks — the largest signal in the incretin class to date — with Phase 3 ongoing and no approved indication as of mid-2026. ## The short version Retatrutide is a single synthetic peptide that does something no previously approved metabolic drug has done: it activates three receptors at once — GIP, GLP-1, and glucagon. The GLP-1 and GIP arms suppress appetite and improve glucose-dependent insulin release; the glucagon arm adds an energy-expenditure component through thermogenic mechanisms. The combination produced a mean 24.2% body-weight reduction versus -2.1% with placebo at 48 weeks in a Phase 2 obesity trial, a larger effect than any prior incretin agent in a comparable trial window [11]. The key boundary to hold clearly: retatrutide is investigational and not approved by any regulatory agency as of mid-2026. All efficacy and safety numbers come from clinical trials, not from approved labeling. It is not available as a prescription or consumer product. Research-grade material circulating outside clinical trials lacks verified identity, purity, and sterility. This page reports what was measured in those trials; it offers no dose and no recommendation. ## What it is Retatrutide (development code LY3437943) is a 39-amino-acid synthetic peptide built on a GIP-based backbone. It carries a C20 fatty-diacid acylation on a lysine side chain for albumin binding, which extends its plasma half-life and supports once-weekly subcutaneous dosing. Its synonyms include *GGG tri-agonist* and *GIP/GLP-1/glucagon receptor triagonist*. You will sometimes see retatrutide called a "GLP-3" or a "triple GLP" in informal sources — these are misnomers. "GLP-3" is not the name of any established receptor class, and the compound's pharmacological identity is the triple GIP/GLP-1/glucagon receptor agonism documented by cryo-EM receptor-complex structures [9]. It is not approved by the FDA or any regulator as of 2026; it remains in the TRIUMPH Phase 3 program under Eli Lilly. ## How it works Retatrutide achieves triple agonism from a single molecule. Cryo-EM structures at 2.68, 3.26, and 2.84 Å resolution show retatrutide engaging GLP-1R, GIPR, and GCGR simultaneously, with receptor-loop conformation differing subtly across the three binding pockets: extracellular loop 1 (ECL1) adopts a rigid alpha-helix at GLP-1R and GCGR but a flexible loop at GIPR, explaining the relative-potency profile [9]. In functional terms, retatrutide is approximately 8.9-fold more potent than native GIP at the GIPR, 0.3-fold at GCGR versus native glucagon, and 0.4-fold at GLP-1R versus native GLP-1 [9]. The GLP-1 arm drives the dominant appetite suppression and gastric-emptying effect. The GIP arm augments insulin secretion in a glucose-dependent manner and modulates fat-cell lipolysis. The glucagon arm, operating at a controlled agonist level, increases energy expenditure via thermogenic signaling — the mechanism proposed to explain both the larger weight-loss signal and the dose-dependent resting heart-rate increase observed in trials [11]. ## What the research shows *Phase 2 obesity trial (-24.2% body weight).* In a 48-week randomized trial of 338 adults with obesity, once-weekly retatrutide at 12 mg produced a mean body-weight change of -24.2% versus -2.1% with placebo. Gastrointestinal adverse events were dose-related and mostly mild to moderate; heart rate increased in a dose-dependent pattern peaking around 24 weeks [11]. *Phase 2 type 2 diabetes trial.* In 281 adults with type 2 diabetes, retatrutide 12 mg reduced HbA1c by 2.02 percentage points at 24 weeks and body weight by 16.94% at 36 weeks, versus -0.01% HbA1c and -3.00% bodyweight with placebo. No severe hypoglycemia and no deaths were reported; mild-to-moderate GI adverse events affected 35% of the highest-dose group [12]. *Liver fat (MASLD substudy).* In a 48-week Phase 2a substudy of 98 participants with obesity or overweight plus metabolic-dysfunction-associated steatotic liver disease (MASLD) and at least 10% baseline liver fat by MRI-PDFF, retatrutide 12 mg reduced relative liver fat by 82.4% at 24 weeks, with 86% of that dose group reaching normal liver fat (less than 5%). Reductions were sustained to 48 weeks (-86.0% at 12 mg) [10]. *Triple-receptor structural basis.* The 2024 cryo-EM study resolved retatrutide's simultaneous binding at all three receptor complexes and confirmed the relative potency ratios, establishing the structural pharmacological basis for the triple-agonist clinical profile [9]. *2025 pharmacology review.* A 2025 review in Biomolecules synthesizes Phase 1/2 data and characterizes the ~24% weight loss as a step-change versus prior incretin therapies, reviewing mechanism, GI and heart-rate safety profiles, and the ongoing Phase 3 program [8]. ![Retatrutide triple-receptor agonism illustration — GIP, GLP-1, and glucagon receptor engagement](/images/retatrutide.webp) ## Reported effects, cautions & safety The following effects and cautions emerge directly from the Phase 2 clinical data and from community self-reports among individuals using retatrutide for research purposes. Community reports are labeled **anecdotal only** — they are unverified self-reports with no confirmed doses or clinical oversight. **Community-reported effects (anecdotal, not clinical evidence)** Individuals using retatrutide in research-use communities frequently describe near-total suppression of what they call *food noise* — intrusive food thoughts — rather than simply feeling full. Rapid and pronounced weight reduction is commonly described. Some reporters note a warmth or mild thermogenic sensation, attributed in community discussion to the glucagon arm's energy-expenditure effects. Mood uplift and a lighter relationship with eating are occasionally mentioned. Commonly reported side effects include: nausea peaking 4-8 hours post-administration (most pronounced during initial weeks and dose escalation), sulfur-smelling burps attributed to slowed gastric motility, fatigue in the first weeks, constipation, and occasionally noticed elevated resting heart rate. Injection-site itching and sleep disturbance are less frequently mentioned. Community members tracking body composition sometimes note concern about lean mass loss alongside fat reduction — a concern mirrored in Phase 2 body-composition data showing absolute lean mass reductions [11]. **Cited safety cautions** - *Investigational status and gray-market risk.* Retatrutide is not approved by any regulator as of mid-2026. Vials from research channels cannot be confirmed to contain authentic retatrutide at stated concentration; independent analyses of similar gray-market peptides have found incorrect sequences or entirely different compounds. The FDA issued over 50 warning letters to retatrutide vendors in 2025. - *Dose-dependent GI adverse events.* Nausea affected up to 45% of participants at the highest Phase 2 dose, the principal driver of the 18% discontinuation rate at that dose [11]. - *Heart-rate elevation.* Phase 2 data document mean heart-rate increases of approximately 5-7 bpm at high doses, peaking around 24 weeks, driven by the glucagon receptor's cardiac chronotropy. A dedicated cardiovascular-outcomes trial (NCT06383390) is ongoing and has not reported results. - *Hypoglycemia interaction.* Retatrutide's GLP-1 and GIP agonism augments insulin secretion; when combined with insulin or sulfonylurea medications, severe hypoglycemia is a risk. Phase 2 diabetic participants on background insulin required insulin de-escalation [12]. - *Lean mass reduction.* A 2025 body-composition substudy confirmed absolute lean-mass reduction alongside fat loss; resistance training and adequate protein intake are protective co-practices discussed in the literature. - *Long-term unknowns.* TRIUMPH Phase 3, dedicated cardiovascular outcomes (NCT06383390), and renal outcomes (TRANSCEND-CKD) trials are all ongoing; no long-term outcomes data exist as of mid-2026. ## Where it fits in metabolic research Among investigational anti-obesity compounds, retatrutide's Phase 2 weight-loss signal is the largest published to date — driven by a pharmacological architecture that combines three distinct metabolic inputs into one weekly injection [8][11]. Its contrast with [tesamorelin](/tesamorelin) is instructive: tesamorelin has approved-drug precision in a narrow population, with effect sizes measured in cm2 of visceral fat; retatrutide has a much larger total bodyweight signal in a broader obesity population, but remains investigational and carries the uncertainties of Phase 3 status. See the [comparison page](/compare) for the full side-by-side. --- A data-forward literature digest — effect sizes and citations, not recommendations, and nothing for sale.